Back to overview
SNCTP000005643 | NCT05681988 | BASEC2022-02216

Frühe, minimal invasive, bildgebungsgesteuerte endoskopische Ausräumung von Hirngewebsblutungen: Eine randomisierte Studie

Data source: BASEC (Imported from 26.07.2024), WHO (Imported from 27.07.2024)
Changed: Jun 11, 2024, 5:48 PM
Disease category: Surgery, Brain diseases (non cancer), Nervous System diseases

Brief description of trial (Data source: BASEC)

In unserem Forschungsvorhaben wollen wir herausfinden, ob die endoskopische (kameragesteuerte) minimal invasive chirurgische Blutungsausräumung innerhalb von 24 Stunden nach Blutungsbeginn besser ist als die momentane Standardtherapie mit Medikamenten. Wenn Sie sich entscheiden teilzunehmen, werden Sie gemäss dem Zufallsprinzip entweder mit der medikamentösen Behandlung und zusätzlich der minimal invasiven endoskopischen Neurochirurgie oder mit der medikamentösen Behandlung alleine therapiert. Sie werden über mehrere Studienvisiten nachbetreut, bei denen Untersuchungen zum Grad der Behinderung durchgeführt und Blutproben abgenommen werden. Die Studie hat 7 Visiten und dauert gesamthaft 12 Monate.

Health conditions investigated(Data source: BASEC)

spontane Hirnblutungen

Health conditions (Data source: WHO)

Intracerebral Haemorrhage

Rare disease (Data source: BASEC)

No

Intervention investigated (e.g. drug, therapy or campaign) (Data source: BASEC)

Bei der Endoskopie handelt es sich um eine Operationsmethode, bei der ein Endoskop mit einer Kamera am Endoskopkopf durch ein kleines Loch im Schädel oberhalb der Blutung in die Blutungshöhle eingeführt wird und die Blutung unter kamerasicht „ausgeräumt“ werden kann. Die kameragesteuerte Therapie ist nicht neu, sie wurde bereits mehrfach angewandt und wird als gleichwertige Therapie gehandelt.

Interventions (Data source: WHO)

Procedure: Early minimally invasive image guided endoscopic hematoma evacuation;Procedure: Best medical treatment (BMT)

Criteria for participation in trial (Data source: BASEC)

Alter zwischen 18 und 85 Jahren
Spontane Hirnblutung mit mindestens 20 mL Volumen
Neurologische Symptome wegen der Blutung
Die Endoskopie kann innerhalb von 24 Stunden nach Blutungsbeginn angefangen werden
Einwilligung des Patienten zur Studienteilnahme liegt vor

Exclusion criteria (Data source: BASEC)

Hirnblutung aufgrund von Trauma, Tumor, Gefässfehlbildung etc.
Mehrere gleichzeitige Hirnblutungen
Hirnblutungen im Kleinhirn oder Hirnstamm
Schwangere Patientinnen
Begleiterkrankungen, die das Überleben in den nächsten 6 Monaten nach Hirnblutung verunmöglichen

Inclusion/Exclusion Criteria (Data source: WHO)

Gender: All
Maximum age: 85 Years
Minimum age: 18 Years

Inclusion Criteria:

- Spontaneous supratentorial intracerebral hemorrhage (SSICH), defined as the sudden
occurrence of bleeding into the lobar parenchyma and/or into the basal ganglia and/or
thalamus that may extend into the ventricles confirmed by imaging

- SSICH volume =20 mL <100 mL

- A focal neurological deficit consisting of either

- clinically relevant hemiparesis (=4 motor points on the NIHSS for facial palsy,
motoric upper and lower extremities combined)

- clinically relevant motor or sensory aphasia (=2 points on the NIHSS)

- clinically relevant hemi-inattention (formerly neglect, 2 points on the NIHSS)

- decreased level of consciousness (Glasgow Coma Scale (GCS)=13)

- Presenting GCS 5 - 15 (in intubated patients GCS assessment will be performed after
Rutledge et al. or if impossible, the last pre-intubation GCS will be used)

- Endoscopic hematoma evacuation can be initiated within 24 hours after the patient was
last seen well/symptom onset

- Informed consent of patient or appropriate surrogate (for patients without competence)

Exclusion Criteria:

- SSICH due to known or suspected structural abnormality in the brain (e.g. vascular
malformation, aneurysm, arteriovenous malformation (AVM), brain tumor) and/or brain
trauma and/or hemorrhagic conversion of an ischemic infarction

- Multiple simultaneous intracranial hemorrhages (ICH) (e.g. multifocal ICH, chronic
subdural hematoma (cSDH), acute subdural hematoma (aSDH), SAH)

- Infratentorial hemorrhage or midbrain extension/involvement of the hemorrhage

- Coagulation disorder (including anticoagulation) with an international normalized
ratio (INR) of >1.5 which cannot be pharmacologically reverted until the planned time
of evacuation

- Pregnancy

- Relevant disability prior to SSICH (mRS >2)

- Any comorbid disease or condition expected to compromise survival or ability to
complete follow-up assessments through 180 days (e.g. bilateral fixed dilated pupils)

Further information on the trial in WHO primary registry

https://clinicaltrials.gov/ct2/show/NCT05681988

Further information on the trial from WHO database (ICTRP)

https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05681988
Further information on trial

Date trial registered

Dec 20, 2022

Recruitment status

Recruiting

Academic title (Data source: WHO)

Early Minimally Invasive Image Guided Endoscopic Evacuation of Intracerebral Haemorrhage (EMINENT-ICH): a Randomized Controlled Trial

Type of trial (Data source: WHO)

Interventional

Design of the trial (Data source: WHO)

Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Phase (Data source: WHO)

N/A

Primary end point (Data source: WHO)

Good functional outcome, measured by the modified Rankin Scale (mRS)

Secundary end point (Data source: WHO)

Mortality rate;Change in Quality of Life, assessed by Patient-Reported Outcomes Measurement Information System (PROMIS?) questionnaire;Change in Patient cognitive outcome as assessed by the Montreal-Cognitive-Assessment-Test (MOCA? );Morbidity rate;Change of focal neurological deficit measured by the National Institute of Health Stroke Scale (NIHSS);Time to intervention;Total time spent on the intensive care unit (ICU)/stroke unit;Total time spent in intubation measured in minutes;Proportion of hematoma volume reduction rate (in the intervention group only);Change in Patient Satisfaction Questionnaire

Contact information (Data source: WHO)

Please refer to primary and secondary sponsors

Trial results (Data source: WHO)

Results summary

no information available yet

Link to the results in the primary register

no information available yet

Information on the availability of individual participant data

no information available yet

Trial sites

Trial sites in Switzerland (Data source: BASEC)

Basel, Bern, Geneva, Lausanne, Lugano, Luzern, Sion, St. Gallen, Winterthur, Zurich

Countries (Data source: WHO)

Switzerland

Contact for further information on the trial

Details of contact in Switzerland (Data source: BASEC)

Tim Jonas Hallenberger
+41 61 556 55 01
tim.hallenberger@usb.ch

Contact for general information (Data source: WHO)

Jehuda Soleman, Prof. Dr. med.;Raphael Guzman, Prof. Dr. med.
Department of Neurosurgery, University Hospital Basel
+41 61 265 33 68
raphael.guzman@usb.ch

Contact for scientific information (Data source: WHO)

Jehuda Soleman, Prof. Dr. med.;Raphael Guzman, Prof. Dr. med.
Department of Neurosurgery, University Hospital Basel
+41 61 265 33 68
raphael.guzman@usb.ch

Authorisation by the ethics committee (Data source: BASEC)

Name of the authorising ethics committee (for multicentre studies only the lead committee)

Ethikkommission Nordwest- und Zentralschweiz EKNZ

Date of authorisation by the ethics committee

15.09.2023

Further trial identification numbers

Trial identification number of the ethics committee (BASEC-ID) (Data source: BASEC)

2022-02216

Secondary ID (Data source: WHO)

ko22Guzman
Back to overview